Vibativ

RSS

Withdrawn

This medicine's authorisation has been withdrawn

telavancin
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Vibativ has been withdrawn at the request of the marketing authorisation holder.

български (BG) (634.53 kB - PDF)

Bekijk

español (ES) (549.37 kB - PDF)

Bekijk

čeština (CS) (617.26 kB - PDF)

Bekijk

dansk (DA) (547.17 kB - PDF)

Bekijk

Deutsch (DE) (552 kB - PDF)

Bekijk

eesti (ET) (546.46 kB - PDF)

Bekijk

ελληνικά (EL) (639.48 kB - PDF)

Bekijk

français (FR) (550.8 kB - PDF)

Bekijk

hrvatski (HR) (1.06 MB - PDF)

Bekijk

italiano (IT) (548.98 kB - PDF)

Bekijk

latviešu (LV) (616.63 kB - PDF)

Bekijk

lietuvių (LT) (577.48 kB - PDF)

Bekijk

magyar (HU) (610.46 kB - PDF)

Bekijk

Malti (MT) (620.67 kB - PDF)

Bekijk

Nederlands (NL) (547.6 kB - PDF)

Bekijk

polski (PL) (615.07 kB - PDF)

Bekijk

português (PT) (549.16 kB - PDF)

Bekijk

română (RO) (576.09 kB - PDF)

Bekijk

slovenčina (SK) (617.05 kB - PDF)

Bekijk

slovenščina (SL) (568.91 kB - PDF)

Bekijk

suomi (FI) (547.15 kB - PDF)

Bekijk

svenska (SV) (548.33 kB - PDF)

Bekijk

Product information

български (BG) (1.66 MB - PDF)

Bekijk

español (ES) (972.49 kB - PDF)

Bekijk

čeština (CS) (1.37 MB - PDF)

Bekijk

dansk (DA) (998.7 kB - PDF)

Bekijk

Deutsch (DE) (1012.89 kB - PDF)

Bekijk

eesti (ET) (990.29 kB - PDF)

Bekijk

ελληνικά (EL) (1.7 MB - PDF)

Bekijk

français (FR) (1.03 MB - PDF)

Bekijk

hrvatski (HR) (1014.8 kB - PDF)

Bekijk

italiano (IT) (1.03 MB - PDF)

Bekijk

latviešu (LV) (1.41 MB - PDF)

Bekijk

lietuvių (LT) (1023.66 kB - PDF)

Bekijk

magyar (HU) (1.37 MB - PDF)

Bekijk

Malti (MT) (1.44 MB - PDF)

Bekijk

Nederlands (NL) (1016.54 kB - PDF)

Bekijk

polski (PL) (1.45 MB - PDF)

Bekijk

português (PT) (1004.82 kB - PDF)

Bekijk

română (RO) (1.06 MB - PDF)

Bekijk

slovenčina (SK) (1.39 MB - PDF)

Bekijk

slovenščina (SL) (1.39 MB - PDF)

Bekijk

suomi (FI) (983.01 kB - PDF)

Bekijk

svenska (SV) (1002.26 kB - PDF)

Bekijk

Íslenska (IS) (985.54 kB - PDF)

Bekijk

norsk (NO) (343.48 kB - PDF)

Bekijk
Latest procedure affecting product information:IAIN/0031
08/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (529.08 kB - PDF)

Bekijk

español (ES) (485.69 kB - PDF)

Bekijk

čeština (CS) (529.3 kB - PDF)

Bekijk

dansk (DA) (485.73 kB - PDF)

Bekijk

Deutsch (DE) (484.5 kB - PDF)

Bekijk

eesti (ET) (485.88 kB - PDF)

Bekijk

ελληνικά (EL) (528.76 kB - PDF)

Bekijk

français (FR) (484.57 kB - PDF)

Bekijk

hrvatski (HR) (492.6 kB - PDF)

Bekijk

italiano (IT) (503.04 kB - PDF)

Bekijk

latviešu (LV) (526.53 kB - PDF)

Bekijk

lietuvių (LT) (502.59 kB - PDF)

Bekijk

magyar (HU) (508.09 kB - PDF)

Bekijk

Malti (MT) (522.89 kB - PDF)

Bekijk

Nederlands (NL) (485.68 kB - PDF)

Bekijk

polski (PL) (523.08 kB - PDF)

Bekijk

português (PT) (485.04 kB - PDF)

Bekijk

română (RO) (509.16 kB - PDF)

Bekijk

slovenčina (SK) (540.33 kB - PDF)

Bekijk

slovenščina (SL) (507.44 kB - PDF)

Bekijk

suomi (FI) (488.95 kB - PDF)

Bekijk

svenska (SV) (485.59 kB - PDF)

Bekijk

Íslenska (IS) (484.25 kB - PDF)

Bekijk

norsk (NO) (469.96 kB - PDF)

Bekijk

български (BG) (700.28 kB - PDF)

Bekijk

español (ES) (613.31 kB - PDF)

Bekijk

čeština (CS) (1.19 MB - PDF)

Bekijk

dansk (DA) (614.54 kB - PDF)

Bekijk

Deutsch (DE) (617.65 kB - PDF)

Bekijk

eesti (ET) (617.52 kB - PDF)

Bekijk

ελληνικά (EL) (697.34 kB - PDF)

Bekijk

français (FR) (618.22 kB - PDF)

Bekijk

italiano (IT) (619.69 kB - PDF)

Bekijk

latviešu (LV) (660.48 kB - PDF)

Bekijk

lietuvių (LT) (634.24 kB - PDF)

Bekijk

magyar (HU) (647.41 kB - PDF)

Bekijk

Malti (MT) (768.5 kB - PDF)

Bekijk

Nederlands (NL) (613.46 kB - PDF)

Bekijk

polski (PL) (699.38 kB - PDF)

Bekijk

português (PT) (625.07 kB - PDF)

Bekijk

română (RO) (643.04 kB - PDF)

Bekijk

slovenčina (SK) (679.65 kB - PDF)

Bekijk

slovenščina (SL) (744.22 kB - PDF)

Bekijk

suomi (FI) (606.41 kB - PDF)

Bekijk

svenska (SV) (612 kB - PDF)

Bekijk

Product details

Name of medicine
Vibativ
Active substance
telavancin
International non-proprietary name (INN) or common name
telavancin
Therapeutic area (MeSH)
  • Pneumonia, Bacterial
  • Cross Infection
Anatomical therapeutic chemical (ATC) code
J01XA03

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).

Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Authorisation details

EMA product number
EMEA/H/C/001240
Marketing authorisation holder
Theravance Biopharma Ireland Umited

Connaught House 1
Burlington Road
Fourth Floor
D04 C5Y6
Dublin 4
Ireland

Marketing authorisation issued
02/09/2011
Revision
10

Assessment history

This page was last updated on

Share this page